Marijuana And Medicine, Cephalopod Week, Environmental Antidepressants. June 18, 2021, Part 1
How To Talk About Medical Marijuana With Your Doctor
Over the last decade, cannabis has had a moment. Thirty-six states and Washington D.C. have legalized it for medical use. (Fifteen states, plus D.C., have also legalized weed recreationally.) Altogether, about 5.5 million people in the U.S. now have medical marijuana cards.
One of the primary arguments for expanding marijuana laws is the drug’s potential usefulness for medical treatments. While each state has its own rules for which conditions are eligible, issues like chronic pain are nearly universally accepted as a reason for using medical marijuana.
But there’s still a large divide between the traditional medical establishment and the cannabis industry. Cannabis is still illegal federally, and a recent study showed that many clinicians feel they don’t know enough about medical marijuana to make a recommendation to patients. This in turn impacts how patients feel about talking to their doctor about using cannabis to treat medical conditions.
Joining Ira to talk about the ins and outs of connecting cannabis to the larger medical establishment are Dr. Ziva Cooper, research director for UCLA’s Cannabis Research Initiative in San Francisco, California, and Dr. Donald Abrams, integrative oncologist and professor emeritus at University of California San Francisco’s Osher Center for Integrative Medicine.
What Can Crayfish Tell Us About Drugs In Our Waterways?
Wastewater is a grab bag of chemicals. There’s industrial run-off, bits of animal and viral DNA, and then there are compounds that trickle out from our households. The medicines we’re flushing down the toilet or releasing through urine are making their way into countless bodies of water.
Antidepressants are one of the drugs that frequently end up in the environment. A team of scientists wanted to study the effects of these antidepressants on streams wending their way through ecosystems. So they looked to none other than the crayfish. They found that crayfish exposed to these drugs were a bit bolder. Their results were published this week in the journal Ecosphere. Freshwater ecologist Lindsey Reisinger and freshwater biogeochemist A.J. Reisinger, who are both authors on that study, talk about how these drugs affect crayfish and potential downstream effects on waterways and the ecosystem.
We Aren’t Squidding Around—It’s Cephalopod Week 2021!
The wait is over—Cephalopod Week 2021 is finally here. It’s Science Friday’s annual ceph-lo-bration of all things mostly-tentacled, and this year’s lineup of events is going to be ceph-tacular.
Diana Montano, SciFri’s outreach manager and emcee of the deep sea, joins Ira and Science Diction host Johanna Mayer to kick things off, with some trivia about the origins of squiddy words.
Kids Are Benefiting From Adult Vaccinations, Too
Something interesting is happening in some communities where most adults are vaccinated against COVID-19: infection rates in kids are going way down, too. Right now, Americans 12 and older are eligible for the vaccine, leaving the country’s youngest still exposed. So this is a promising sign, considering about two-thirds of U.S. adults have received at least one shot of a COVID-19 vaccine.
But some experts are saying we still need to be cautious about throwing kids together again before they’re vaccinated. Joining Ira to chat about this story is Maggie Koerth, senior science writer at FiveThirtyEight in Minneapolis, Minnesota. They also talk about other top science stories of the week, including news that cicada broods might emerge more often with climate change.
Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that’s keeping you up at night? Call us: 877-472-4374
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Available Results
Generated results are saved to your library for reuse and search.
Choose Template
Pick the result you want. You can review provider and model before generating.
A concise first-pass summary for understanding the episode quickly.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
A comprehensive extraction focused on opportunities, strategy, markets, and company building.
Explicit actions, next steps, habits, recommendations, and things to avoid.
Repeatable methods, frameworks, mental models, processes, and systems.
A dedicated inventory of concrete resources named in the episode.
A concise first-pass summary for understanding the episode quickly.
A detailed readable summary organized by chapter or topic.
A navigable map of subjects, topic flow, and suggested chapters.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
Reusable atomic knowledge units extracted from the episode.
A comprehensive extraction focused on health practices, protocols, claims, and safety caveats.
A comprehensive extraction focused on opportunities, strategy, markets, and company building.
Explicit actions, next steps, habits, recommendations, and things to avoid.
A dedicated inventory of concrete resources named in the episode.
A dedicated analysis of warnings, limitations, trade-offs, weak evidence, and uncertainty.
A concise first-pass summary for understanding the episode quickly.
A detailed readable summary organized by chapter or topic.
A navigable map of subjects, topic flow, and suggested chapters.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
Reusable atomic knowledge units extracted from the episode.
A comprehensive extraction focused on health practices, protocols, claims, and safety caveats.
A comprehensive extraction focused on opportunities, strategy, markets, and company building.
Scientific findings, mechanisms, studies, hypotheses, and the limits of the evidence discussed.
Technologies, AI models, technical methods, capabilities, limitations, and adoption implications.
Investment theses, assets, catalysts, valuation reasoning, time horizons, and risks.
Chronologies, actors, causes, consequences, turning points, and competing historical interpretations.
Policies, proposals, stakeholders, arguments, implementation constraints, and predicted effects.
Career paths, skills, hiring signals, workplace decisions, transitions, and limitations of the advice.
Behavioral mechanisms, biases, motivation, habits, emotions, interventions, and evidence limitations.
Economic mechanisms, incentives, indicators, market structure, forecasts, and uncertainty.
Leadership principles, team systems, organizational design, culture, feedback, and failure modes.
Audience, positioning, messaging, acquisition, retention, experiments, metrics, and failed approaches.
Teaching methods, learning strategies, practice, feedback, assessment, and effectiveness evidence.
Theses, premises, arguments, objections, values, thought experiments, and unresolved questions.
Communication patterns, conflict, boundaries, expectations, repair methods, and contextual limitations.
Books, papers, authors, courses, and other learning resources mentioned in the episode.
Repeatable methods, frameworks, mental models, processes, and systems.
Explicit actions, next steps, habits, recommendations, and things to avoid.
Memorable statements and important claims with attribution and source context.
A dedicated inventory of concrete resources named in the episode.
A dedicated analysis of warnings, limitations, trade-offs, weak evidence, and uncertainty.